Organovo Holdings, INC.: management transactions · United States · SEC (Form 4)

About Organovo Holdings, INC.

Organovo Holdings, Inc. is a United States-based biotechnology company listed on the NASDAQ market. For French-, Belgian- and Swiss-based investors, it should be viewed as a small-cap healthcare name with a highly speculative, innovation-driven profile rather than as a mature commercial drug company. The company became known for its proprietary 3D bioprinting and human tissue engineering capabilities, designed to create three-dimensional human tissues that better mimic native tissue architecture and disease biology than conventional cell models. Its operational headquarters is in San Diego, California, and the business has historically maintained U.S.-based development and manufacturing capabilities. ([ir.organovo.com](https://ir.organovo.com/?utm_source=openai)) Organovo’s origins are tied to an early scientific thesis: using 3D human tissue models to improve drug discovery, preclinical testing, and disease modeling. That technological positioning gave the company a differentiated niche versus broader biotech peers. More recently, however, the company has moved further toward drug development, with FXR314 highlighted as its lead molecule and a program with potential in inflammatory bowel disease as well as possible applications in metabolic disease and oncology. This evolution indicates a strategic shift from platform-only commercialization toward a more classic biotech value-creation model built around a lead therapeutic asset. ([ir.organovo.com](https://ir.organovo.com/?utm_source=openai)) From a business-model perspective, Organovo has effectively operated around two core activities: its 3D human tissue technology and the related research/development opportunity set, and a drug-discovery pipeline derived from that scientific base. Its customer and partner universe is therefore centered on pharmaceutical and biomedical research organizations, with the long-term investment case depending on whether its technology can generate repeatable commercial demand and whether its pipeline can advance through clinical milestones. In competitive terms, Organovo remains a niche specialist rather than a scale player, and it competes against far larger life-science and biotech companies with deeper capital bases. ([ir.organovo.com](https://ir.organovo.com/?utm_source=openai)) Recent corporate developments are especially important. In 2025, the company said its 3D bioprinting business would be carried forward by VivoSim, marking a further strategic transition. The most material event was the March 2025 sale of the FXR program to Eli Lilly for $10 million upfront, plus potential milestone payments of up to $50 million if development, regulatory, and commercial targets are achieved. Organovo also updated investors on cash and NASDAQ continued-listing requirements in April 2025, underscoring the financing and listing risk that typically accompanies early-stage biotech companies. For investors, the stock remains a high-risk, event-driven healthcare name with scientific optionality but limited operational visibility. ([ir.organovo.com](https://ir.organovo.com/press-releases/?utm_source=openai))